From the Guidelines
Dynaglipt is not a recognized medication or medical term in standard medical practice. It appears to be a made-up or fictional name that doesn't correspond to any approved pharmaceutical product, medical device, or established medical concept. If you're looking for information about a diabetes medication, you might be referring to drugs in the "gliptin" class (DPP-4 inhibitors) such as sitagliptin (Januvia), saxagliptin (Onglyza), or linagliptin (Tradjenta) 1. These medications work by increasing incretin levels, which inhibit glucagon release, increase insulin secretion, and slow gastric emptying to help control blood sugar in type 2 diabetes patients.
Some key points to consider when looking at DPP-4 inhibitors include:
- They have moderate glucose-lowering efficacy 1
- They are well tolerated, have a neutral effect on weight, and have minimal risk of hypoglycemia when used as monotherapy 1
- However, when added to sulfonylurea therapy, the risk for hypoglycemia is increased 50% compared with sulfonylurea therapy alone 1
- Rare but increased rates of pancreatitis and musculoskeletal side effects have been reported 1
- The American College of Physicians recommends against adding a DPP-4 inhibitor to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control to reduce morbidity and all-cause mortality 1
If you're seeking information about a specific medication, I recommend checking the exact spelling on your prescription or consulting with your healthcare provider for accurate information about your medication, its dosage, and proper use. Additionally, considering the most recent guidelines, the use of SGLT-2 inhibitors or GLP-1 agonists is recommended over DPP-4 inhibitors for adults with type 2 diabetes and inadequate glycemic control 1.
From the Research
Definition and Mechanism of Action
- Dynaglipt is not explicitly mentioned in the provided studies, however, based on the context, it can be inferred that the question is referring to Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus 2, 3, 4, 5, 6.
- Saxagliptin works by inhibiting the DPP-4 enzyme, which is responsible for the degradation of incretin hormones, thereby increasing the levels of these hormones and enhancing their actions 2, 3, 4, 5, 6.
Efficacy and Safety
- Clinical trials have demonstrated that saxagliptin is effective in improving glycemic control, reducing fasting and postprandial glucose concentrations, and lowering glycated hemoglobin levels 2, 3, 4, 5, 6.
- Saxagliptin has been shown to be well-tolerated, with a side-effect profile similar to placebo, and a low risk of hypoglycemia due to its glucose-dependent mechanism of action 2, 3, 4, 5, 6.
Dosage and Administration
- The usual adult dose of saxagliptin is 2.5 to 5 mg once daily, regardless of meals, with a recommended dose of 2.5 mg for patients with moderate to severe renal impairment or those taking potent CYP 3A4 inhibitors 2, 3.
- Saxagliptin can be used alone or in combination with other antidiabetic agents, such as metformin, sulfonylurea, or thiazolidinedione, to achieve adequate glucose control 2, 3, 4, 5, 6.